247 related articles for article (PubMed ID: 36105233)
1. Nucleic acid strategies for infectious disease treatments: The nanoparticle-based oral delivery route.
Chen F; Liu Q; Xiong Y; Xu L
Front Pharmacol; 2022; 13():984981. PubMed ID: 36105233
[TBL] [Abstract][Full Text] [Related]
2. Oral nucleic acid therapy using multicompartmental delivery systems.
Attarwala H; Han M; Kim J; Amiji M
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2018 Mar; 10(2):. PubMed ID: 28544521
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease.
Li DF; Yang MF; Xu HM; Zhu MZ; Zhang Y; Tian CM; Nie YQ; Wang JY; Liang YJ; Yao J; Wang LS
J Mater Chem B; 2022 Aug; 10(31):5853-5872. PubMed ID: 35876136
[TBL] [Abstract][Full Text] [Related]
4. Oral delivery of non-viral nucleic acid-based therapeutics - do we have the guts for this?
O'Driscoll CM; Bernkop-Schnürch A; Friedl JD; Préat V; Jannin V
Eur J Pharm Sci; 2019 May; 133():190-204. PubMed ID: 30946964
[TBL] [Abstract][Full Text] [Related]
5. Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract.
Kriegel C; Attarwala H; Amiji M
Adv Drug Deliv Rev; 2013 Jun; 65(6):891-901. PubMed ID: 23220324
[TBL] [Abstract][Full Text] [Related]
6. Nanomedicine-based delivery strategies for nucleic acid gene inhibitors in inflammatory diseases.
Fattal E; Fay F
Adv Drug Deliv Rev; 2021 Aug; 175():113809. PubMed ID: 34033819
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-mediated gene therapy strategies for mitigating inflammatory bowel disease.
Verma P; Srivastava A; Srikanth CV; Bajaj A
Biomater Sci; 2021 Mar; 9(5):1481-1502. PubMed ID: 33404019
[TBL] [Abstract][Full Text] [Related]
8. Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease.
Shinn J; Lee J; Lee SA; Lee SJ; Choi AH; Kim JS; Kim SJ; Kim HJ; Lee C; Kim Y; Kim J; Choi J; Jung B; Kim T; Nam H; Kim H; Lee Y
Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145716
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
Yang C; Merlin D
Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
[TBL] [Abstract][Full Text] [Related]
10. Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease.
Zhang Y; Thanou M; Vllasaliu D
Eur J Pharm Biopharm; 2020 Oct; 155():128-138. PubMed ID: 32853696
[TBL] [Abstract][Full Text] [Related]
11. The future of nanomedicine in optimising the treatment of inflammatory bowel disease.
Mohan LJ; Daly JS; Ryan BM; Ramtoola Z
Scand J Gastroenterol; 2019 Jan; 54(1):18-26. PubMed ID: 30678499
[TBL] [Abstract][Full Text] [Related]
12. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease.
Shrestha N; Xu Y; Prévost JRC; McCartney F; Brayden D; Frédérick R; Beloqui A; Préat V
Acta Biomater; 2022 Mar; 140():561-572. PubMed ID: 34923097
[TBL] [Abstract][Full Text] [Related]
13. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue.
Hua S; Marks E; Schneider JJ; Keely S
Nanomedicine; 2015 Jul; 11(5):1117-32. PubMed ID: 25784453
[TBL] [Abstract][Full Text] [Related]
14. Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases.
Zu M; Ma Y; Cannup B; Xie D; Jung Y; Zhang J; Yang C; Gao F; Merlin D; Xiao B
Adv Drug Deliv Rev; 2021 Sep; 176():113887. PubMed ID: 34314785
[TBL] [Abstract][Full Text] [Related]
15. Intranasal delivery: An attractive route for the administration of nucleic acid based therapeutics for CNS disorders.
Shah P; Lalan M; Barve K
Front Pharmacol; 2022; 13():974666. PubMed ID: 36110526
[TBL] [Abstract][Full Text] [Related]
16. Engineering strategies to enhance nanoparticle-mediated oral delivery.
Yamanaka YJ; Leong KW
J Biomater Sci Polym Ed; 2008; 19(12):1549-70. PubMed ID: 19017470
[TBL] [Abstract][Full Text] [Related]
17. Role of nanostructures in improvising oral medicine.
Ghosh S; Ghosh S; Sil PC
Toxicol Rep; 2019; 6():358-368. PubMed ID: 31080743
[TBL] [Abstract][Full Text] [Related]
18. Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy.
Zhang C; Ma Y; Zhang J; Kuo JC; Zhang Z; Xie H; Zhu J; Liu T
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335310
[TBL] [Abstract][Full Text] [Related]
19. Nucleic acid delivery and nanoparticle design for COVID vaccines.
Andresen JL; Fenton OS
MRS Bull; 2021; 46(9):832-839. PubMed ID: 34539057
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory bowel disease and targeted oral anti-TNFα therapy.
Griffiths OR; Landon J; Coxon RE; Morris K; James P; Adams R
Adv Protein Chem Struct Biol; 2020; 119():157-198. PubMed ID: 31997768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
